Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ABLYNX (D) : ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 29TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/04/2011 | 06:10pm CET

GHENT, Belgium, 4 January 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, 11 January 2011 at 11.00 a.m. PST / 08.00 p.m. CET.

 

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx's website at www.ablynx.com:
http://www.ablynx.com/. A replay of the webcast will also be available on the Company's website for 30 days following the presentation.

 

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

 

 

About Ablynx

Ablynx:
http://www.ablynx.com/ (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and Alzheimer's disease. Today, the Company has over 25 projects in the pipeline:
http://www.ablynx.com/en/research-development/pipeline/ and there are five Nanobodies in clinical development. In parallel with its internally developed products, Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 250 people. More information can be found on www.ablynx.com:
http://www.ablynx.com/.

 

 

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1477060/413118.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE


HUG#1477060


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
02/16 ABLYNX : 16/02/2017 ablynx will announce its 2016 full year results with webcast..
02/16 Ablynx will announce its 2016 full year results with webcast on 23 february 2..
02/16 ABLYNX : Will announce its 2016 full year results with webcast on 23 february 20..
02/09 ABLYNX : 09/02/2017 ablynx to present additional data for its anti-il-6r nanobod..
02/09 ABLYNX : To present additional data for its anti-il-6r nanobody, vobarilizumab, ..
02/06 ABLYNX : 06/02/2017 ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE ..
02/06 ABLYNX : SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES..
01/26 ABLYNX : 26/01/2017 ABLYNX'S PARTNER, MERCK KGaA, REPORTS ENCOURAGING RESULTS WI..
01/26 ABLYNX : PARTNER, MERCK KGaA, REPORTS ENCOURAGING RESULTS WITH THE BI-SPECIFIC N..
01/24 ABLYNX : 24/01/2017 van herk investments b.v. announces 10.07% shareholding in a..
More news
Sector news : Biotechnology & Medical Research - NEC
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
2016 Ablynx NV reports 9M results
2016 ARGENX : The New Ablynx?
2016 A European Biotech Stock Basket For 2016 - Update
2016 Why Abbvie Won't Pull A Galapagos On Ablynx
Advertisement
Financials (€)
Sales 2016 80,7 M
EBIT 2016 -20,8 M
Net income 2016 -4,80 M
Finance 2016 43,3 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 8,89x
EV / Sales 2017 17,3x
Capitalization 761 M
More Financials
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 15,6 €
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX15.26%808
INCYTE CORPORATION20.17%22 822
QUINTILES IMS HOLDINGS..0.92%18 894
CELLTRION, INC.--.--%10 747
LONZA GROUP AG1.87%10 368
SEATTLE GENETICS, INC.24.12%9 272
More Results